Research Analysts Forecast Genelux Earnings for Q1 2025

Genelux Co. (NASDAQ:GNLX - Free Report) is attracting attention from equity research analysts, particularly from HC Wainwright, which recently shared its predictions for the company’s financial performance in the first quarter of 2025. According to a research note published on March 25th, analyst E. Bodnar anticipates that Genelux will report earnings per share (EPS) of approximately ($0.16) for Q1 2025.

HC Wainwright currently holds a "Buy" rating on Genelux and has set a target price of $30.00 for the stock. In addition to the Q1 predictions, the firm has provided estimates for subsequent quarters. They expect Genelux to achieve a similar EPS of ($0.16) in the second quarter of 2025, followed by ($0.19) in the third quarter, and ($0.22) in the fourth quarter. For the full fiscal year of 2029, the earnings prediction stands at $2.58 per share.

Stock Performance Overview

As of Wednesday, shares of GNLX were priced at $3.40. Over the past year, the stock has experienced a low of $1.60 and a high of $6.50. Current performance indicators show a fifty-day moving average at $4.02 and a two-hundred day moving average at $3.09. The company has a market capitalization of $117.43 million and reports a price-to-earnings (P/E) ratio of -3.58, with a beta of -1.41 indicating its volatility relative to the market.

Institutional Investors and Hedge Funds Activity

Recent trading activity indicates that various institutional investors and hedge funds are becoming involved with Genelux. For instance, Virtu Financial LLC initiated a new position in the company during the fourth quarter, investing approximately $25,000. Apollon Wealth Management LLC increased its stake in Genelux by 20.4% during the same period, bringing its total holding to 16,863 shares valued at approximately $40,000. Other notable investors include Raymond James Financial Inc., which acquired shares worth $41,000, and Brown Brothers Harriman & Co., which has also increased its stake significantly. Currently, 37.33% of Genelux shares are held by institutional entities.

About Genelux Corporation

Genelux Corporation operates in the clinical-stage biopharmaceutical sector, focusing on developing advanced oncolytic viral immunotherapies. These therapies are aimed at patients with challenging solid tumors. The firm’s leading product candidate is Olvi-Vec, a modified strain of the vaccinia virus designed to target ovarian cancer and non-small cell lung cancer.

Considerations for Investors

Potential investors should be aware that while Genelux has received positive ratings, analysts have identified several alternative stocks as potentially better investment opportunities. Before making investment decisions regarding Genelux, stakeholders may wish to consider a comprehensive study of available market insights and seek advice based on updated analyst recommendations.

Genelux, Earnings, Stock